Purchase Order 75N93019P00764

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $11,179.50 on November 18, 2019, for customized gene production, gene synthesis, and cloning services.</p> <p>Place of performance is Piscataway, New Jersey. The order carries a firm fixed price and ultimate completion date of December 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $249,943.63 on September 16, 2019. The order covers DNA synthesis, plasmid, and protein production services. Work is performed in Piscataway, New Jersey. The purchase order is firm fixed price with an ultimate completion date of January 31, 2020. The order originated from a pre-solicitation opportunity posted September 11, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $15,028.93 on September 10, 2015, for mutagenesis, gene synthesis, custom plasmid preparation, and reagents. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and no set-aside designation. Ultimate completion is September 13, 2016.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on September 3, 2022, for gene synthesis plasmid preparation services, with a firm fixed price ceiling of $48,665.65. Place of performance is Piscataway, New Jersey. The work supports the FY26 UDO Initiative and was sourced through a pre-solicitation opportunity posted August 24, 2022, with a September 2 deadline. Ultimate completion is scheduled for September 29, 2022.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized DNA and monoclonal antibody production, valued at $49,653.58, on August 6, 2020. Performance is located in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 5, 2020.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $14,756.36 on September 13, 2021, for sequencing services under the FY26 UDO Initiative. Performance is at Genscript's facility in Piscataway, New Jersey. The order carries a firm fixed price and was completed by December 31, 2021.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $30,200.12 on September 11, 2017. Performance is at Genscript's facility in Piscataway, New Jersey. The order was firm fixed price with no small business set-aside. Ultimate completion was September 18, 2017.</p>